This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Celgene Corporation (NASDAQ:CELG) announced that Celgene management will provide an overview of the Company at two upcoming investor conferences in the month of September. The conferences will be webcast live and a link to the webcasts will be available in the Investor Relations section of the Company’s website at
Thursday, September 4, 2014 at the 9 th Annual Citi Biotech Conference in Boston at 10 a.m. ET
Tuesday, September 9, 2014 at the Morgan Stanley Global Healthcare Conference in New York at 12:55 p.m. ET
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit
www.celgene.com. Follow us on Twitter @Celgene as well.
Forward-Looking StatementsThis press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.